BioLineRx (NASDAQ:BLRX) Upgraded by StockNews.com to “Sell”

StockNews.com upgraded shares of BioLineRx (NASDAQ:BLRX) to a sell rating in a research note published on Wednesday morning.

Separately, HC Wainwright reissued a buy rating and issued a $21.00 price target on shares of BioLineRx in a report on Tuesday.

BioLineRx Stock Performance

Shares of BLRX opened at $1.11 on Wednesday. BioLineRx has a 12 month low of $0.81 and a 12 month high of $2.53. The company’s fifty day moving average is $1.21 and its 200-day moving average is $1.47. The company has a quick ratio of 1.86, a current ratio of 1.96 and a debt-to-equity ratio of 0.64. The firm has a market cap of $80.41 million, a price-to-earnings ratio of -1.32 and a beta of 1.40.

BioLineRx (NASDAQ:BLRX) last posted its earnings results on Tuesday, March 26th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.07. The firm had revenue of $4.80 million during the quarter, compared to analyst estimates of $0.17 million. During the same quarter in the previous year, the business posted ($0.09) earnings per share. Equities analysts expect that BioLineRx will post -0.98 EPS for the current fiscal year.

Institutional Investors Weigh In On BioLineRx

A number of hedge funds have recently made changes to their positions in BLRX. Renaissance Technologies LLC increased its position in shares of BioLineRx by 377.6% during the 1st quarter. Renaissance Technologies LLC now owns 67,346 shares of the biotechnology company’s stock worth $115,000 after purchasing an additional 53,246 shares in the last quarter. Atria Wealth Solutions Inc. acquired a new stake in BioLineRx in the 1st quarter valued at about $178,000. LPL Financial LLC increased its position in BioLineRx by 152.7% in the 4th quarter. LPL Financial LLC now owns 117,710 shares of the biotechnology company’s stock valued at $69,000 after acquiring an additional 71,134 shares in the last quarter. Envestnet Asset Management Inc. acquired a new stake in BioLineRx in the 1st quarter valued at about $88,000. Finally, Geneos Wealth Management Inc. increased its position in BioLineRx by 72.3% in the 3rd quarter. Geneos Wealth Management Inc. now owns 40,500 shares of the biotechnology company’s stock valued at $74,000 after acquiring an additional 17,000 shares in the last quarter. Institutional investors and hedge funds own 1.56% of the company’s stock.

About BioLineRx

BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia.